X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (90) 90
middle aged (60) 60
adult (57) 57
female (53) 53
male (52) 52
oncology (52) 52
aged (41) 41
hematology (27) 27
antineoplastic combined chemotherapy protocols - therapeutic use (26) 26
remission induction (22) 22
acute disease (21) 21
treatment outcome (20) 20
adolescent (19) 19
cancer (15) 15
survival analysis (15) 15
therapy (15) 15
prognosis (13) 13
bone marrow transplantation (12) 12
chemotherapy (12) 12
follow-up studies (12) 12
acute myelogenous leukemia (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (11) 11
combined modality therapy (11) 11
drug evaluation (11) 11
leukemia, myeloid, acute - drug therapy (11) 11
medicine, general & internal (11) 11
aged, 80 and over (10) 10
cytarabine - administration & dosage (10) 10
disease-free survival (10) 10
index medicus (10) 10
leukemia, myeloid - drug therapy (10) 10
survival rate (10) 10
antineoplastic agents - therapeutic use (9) 9
antineoplastic combined chemotherapy protocols - administration & dosage (9) 9
leukemia - drug therapy (9) 9
acute myeloid leukemia (8) 8
cyclophosphamide - administration & dosage (8) 8
acute lymphoblastic-leukemia (7) 7
acute nonlymphocytic leukemia (7) 7
antineoplastic agents - adverse effects (7) 7
article (7) 7
daunorubicin - administration & dosage (7) 7
doxorubicin - administration & dosage (7) 7
karyotyping (7) 7
leukemia, myeloid - mortality (7) 7
lymphoma, non-hodgkin - drug therapy (7) 7
acupuncture (6) 6
care and treatment (6) 6
complementary therapies (6) 6
immunophenotyping (6) 6
leukemia (6) 6
methotrexate - administration & dosage (6) 6
non-hodgkins-lymphoma (6) 6
prednisone - administration & dosage (6) 6
toxicity (6) 6
vincristine - administration & dosage (6) 6
1st remission (5) 5
acute myeloid-leukemia (5) 5
bone-marrow transplantation (5) 5
chromosome aberrations (5) 5
clinical trials as topic (5) 5
cytarabine - adverse effects (5) 5
cytarabine - therapeutic use (5) 5
drug administration schedule (5) 5
etoposide - administration & dosage (5) 5
leukemia - complications (5) 5
leukemia, hairy cell - drug therapy (5) 5
leukemia, myeloid - therapy (5) 5
neoplasms (5) 5
pentostatin - therapeutic use (5) 5
prednisone - therapeutic use (5) 5
prospective studies (5) 5
recurrence (5) 5
retrospective studies (5) 5
time factors (5) 5
transplantation, autologous (5) 5
tumors (5) 5
acute promyelocytic leukemia (4) 4
agranulocytosis - complications (4) 4
bone marrow - drug effects (4) 4
bone marrow - pathology (4) 4
cancer patients (4) 4
cells (4) 4
clinical-trials (4) 4
complete remission (4) 4
etoposide - adverse effects (4) 4
etoposide - therapeutic use (4) 4
genetics & heredity (4) 4
high-dose cytarabine (4) 4
leukemia, myeloid, acute - mortality (4) 4
leukemia, myeloid, acute - therapy (4) 4
lung neoplasms - therapy (4) 4
lymphoma, non-hodgkin - mortality (4) 4
lymphomas (4) 4
non-hodgkin's lymphoma (4) 4
patients (4) 4
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (4) 4
prednisone - adverse effects (4) 4
prognostic factors (4) 4
psychological aspects (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer, ISSN 0008-543X, 11/2010, Volume 116, Issue 21, pp. 5012 - 5021
BACKGROUND: Patients with newly diagnosed acute myeloid leukemia (AML) often have residual leukemia in the bone marrow 10 to 14 days after the start of... 
induction therapy | prognostic factors | acute myeloid leukemia | residual disease | complete remission | Complete remission | Residual disease | Acute myeloid leukemia | Induction therapy | Prognostic factors
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 1315 - 1315
Abstract This study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L. Comis, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and... 
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 4779 - 4779
Abstract Abstract 4779 Purpose: The Stanford V regimen is a combined modality approach for treatment of Hodgkin lymphoma (HL). E1492, an ECOG pilot study,... 
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 63 - 63
Abstract Background Extramedullary disease (EMD) of acute myeloid leukemia (AML) was described decades ago but the incidence of this phenomenon and its... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 132 - 132
Abstract Abstract 132 Late relapse in acute myeloid leukemia (AML) has been infrequently studied and variably defined in the literature. Two series have shown... 
Journal Article
Leukemia Research, ISSN 0145-2126, 08/2014, Volume 38, Issue 8, pp. 901 - 906
We examined 1229 younger patients with acute myeloid leukemia who achieved CR1 on Eastern Cooperative Oncology Group trials. We defined late relapse as... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.